This paper discusses the link between pharmacogenetics and race, and the global justice issues that the introduction of pharmacogenetics in pharmaceutical research and clinical practice will raise. First, it briefly outlines the likely impact of pharmacogenetics on pharmaceutical research and clinical practice within the next five to ten years and then explores the link between pharmacogenetic traits and 'race'. It is shown that any link between apparent race and pharmacogenetics is problematic and that race cannot be used as a proxy for pharmacogenetic knowledge. The final section considers the implications of the development of pharmacogenetics for health care systems in low- and middle-income countries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1471-8847.2006.00173.x | DOI Listing |
Genet Med
October 2024
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA; William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.
Purpose: Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a national healthcare system where panel-based testing was implemented as part of routine care.
Methods: We used a retrospective matched cohort design and data from the Veterans Health Administration Corporate Data Warehouse.
Clin Transl Sci
October 2024
Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Clin Transl Sci
September 2024
Botswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Heliyon
September 2024
Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador.
Based on data from the Global Cancer Statistics 2022, lung cancer stands as the most lethal cancer worldwide, with age-adjusted incidence and mortality rates of 23.6 and 16.9 per 100,000 people, respectively.
View Article and Find Full Text PDFS Afr Med J
April 2024
Wits Donald Gordon Medical Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa.
Background: In the paediatric liver transplant programme in Johannesburg, South Africa (SA), tacrolimus is the calcineurin inhibitor of choice, comprising an essential component of the immunosuppression regimen. It is characterised by a narrow therapeutic index and wide interpatient variability, necessitating therapeutic drug monitoring of whole-blood concentrations. Pharmacogenetic research, although not representative of SA population groups, suggests that single-nucleotide polymorphisms within the cytochrome P450 3A5 (CYP3A5) gene contribute to the variability in tacrolimus dosing requirements.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!